Dear all,

Please spread the announcement below as you see fit.

 

Best

Celia

 

 

Dr. Celia W.G. van Gelder

Programme Manager Learning DTL/ELIXIR-NL Training
Education Manager BioSB

ELIXIR Training Platform Leader

tel. +31613375327

e-mail: celia.van.gelder@dtls.nl

websites:  www.dtls.nl, www.biosb.nl

skype: celia.van.gelder

 

Postal address:

DTL
PO Box 19245

3501 DE Utrecht

 

 

 

This is to inform you that registration for the next free C-COMEND course is still open.  The EU project C-COMEND offers PhD and Postdocs the opportunity to join a course on “Translational Research and Development“ in Berlin from 9th-13th of October 2017.

The course consists of an introductory e‑learning (~ 24 hours student investment time) followed by a 5-day face-to-face workshop with speakers from Industry and Academia, including

 

    Bob Harris, Professor Immunotherapy, Karolinska

    Matthias Gottwald, Head of R&D Policy & Networking, BAYER

    Keith Williams, Director, KW Drug Developments

    Mike Hardman, former Vice President IMI Collaborations, AstraZeneca

    Mohamed Abou-El-Enein, Head of Clinical Development Platform, BCRT

 

Participation is free of charge but participants will have to cover their travel costs.

Deadline for application is June, 1st

 

It would be fantastic if you could support us by spreading this information to your colleagues, students and/ or other people in your network that might be interested, either by sharing this email  (see also the attached flyer and preliminary program) or via twitter, or LinkedIn and facebook.

 

Thank you very much in advance for your time and effort!

 

With kind regards,

 

 

Rosan Vegter, DVM, PhD

C-Comend Training Project Manager

 

cid:image001.png@01D2D928.60139120

 

 

EATRIS |  European infrastructure for translational medicine

 

rosanvegter@eatris.eu | +31 (0)6 15 52 29 34

De Boelelaan 1118 | Room PK 4X 176

1081 HZ Amsterdam | The Netherlands

+31 (0)20 4442254 | www.eatris.eu

Working days: Monday, Tuesday, Friday

 

Follow us on Twitter

 

cid:image002.png@01D2D928.60139120